Allergan Stock Price, News & Analysis (NYSE:AGN)

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan declared a quarterly dividend on Friday, July 19th. Stockholders of record on Tuesday, August 13th will be given a dividend of $0.74 per share on Friday, September 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.75%. The ex-dividend date is Monday, August 12th. View Allergan's Dividend History.

Allergan announced that its Board of Directors has approved a share buyback program on Tuesday, January 29th 2019, which allows the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 4.1% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's leadership believes its shares are undervalued.

Allergan plc (NYSE:AGN) posted its earnings results on Tuesday, August, 6th. The company reported $4.38 earnings per share for the quarter, topping the Zacks' consensus estimate of $4.34 by $0.04. The firm earned $4.09 billion during the quarter, compared to the consensus estimate of $3.93 billion. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. Allergan's revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the business posted $4.42 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Allergan.

Allergan updated its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of >$16.55 for the period, compared to the Thomson Reuters consensus estimate of $16.74. The company issued revenue guidance of 15.4-15.6 billion, compared to the consensus revenue estimate of $15.32 billion.

21 brokerages have issued 1 year price targets for Allergan's stock. Their predictions range from $144.95 to $255.00. On average, they expect Allergan's stock price to reach $179.15 in the next year. This suggests a possible upside of 6.0% from the stock's current price. View Analyst Price Targets for Allergan.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 15 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

Press coverage about AGN stock has trended negative on Monday, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Allergan earned a coverage optimism score of -2.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Allergan.

Allergan saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 10,330,000 shares, an increase of 8.9% from the August 30th total of 9,490,000 shares. Based on an average trading volume of 3,600,000 shares, the days-to-cover ratio is presently 2.9 days. Approximately 3.2% of the company's stock are short sold. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Bayer (BAYRY) and Zoetis (ZTS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Metropolis Capital Ltd (0.05%), State of Alaska Department of Revenue (0.02%), Havens Advisors LLC (0.02%), Alpine Group USVI LLC (0.01%), Gibraltar Capital Management Inc. (0.01%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Metropolis Capital Ltd, Nelson Van Denburg & Campbell Wealth Management Group LLC, Gofen & Glossberg LLC IL, Welch & Forbes LLC, Arden Trust Co, Gibraltar Capital Management Inc., Crossmark Global Holdings Inc. and Bremer Bank National Association. View Insider Buying and Selling for Allergan.

AGN stock was purchased by a variety of institutional investors in the last quarter, including Alpine Group USVI LLC, Havens Advisors LLC, State of Alaska Department of Revenue, Cerebellum GP LLC, Cerebellum GP LLC, Legacy Private Trust Co., Clarus Wealth Advisors and Berkshire Asset Management LLC PA. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $169.09.

Allergan has a market capitalization of $55.47 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]